Trials / Approved For Marketing
Approved For MarketingNCT03862885
Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST
Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Blueprint Medicines Corporation · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- —
Summary
This is a US, multicenter, open-label expanded access program to provide access to avapritinib until such time that avapritinib becomes available through other mechanisms or the Sponsor chooses to discontinue the program.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avapritinib | Avapritinib will be administered orally (PO) at a dose of 300 mg once daily (QD) in continuous 28-day cycles. |
Timeline
- First posted
- 2019-03-05
- Last updated
- 2020-07-27
Source: ClinicalTrials.gov record NCT03862885. Inclusion in this directory is not an endorsement.